Zura Bio (ZURA) Competitors

Zura Bio (NASDAQ:ZURA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Does the media favor ZURA or TRDA?

In the previous week, Entrada Therapeutics had 4 more articles in the media than Zura Bio. MarketBeat recorded 9 mentions for Entrada Therapeutics and 5 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.77 beat Entrada Therapeutics' score of 0.38 indicating that Zura Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher valuation and earnings, ZURA or TRDA?

Entrada Therapeutics has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$69.24M	-$0.70	-1.49
Entrada Therapeutics	$172.22M	1.78	-$6.68M	$0.81	9.99

Which has more volatility and risk, ZURA or TRDA?

Zura Bio has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500.

Is ZURA or TRDA more profitable?

Entrada Therapeutics has a net margin of 25.53% compared to Zura Bio's net margin of 0.00%. Entrada Therapeutics' return on equity of 16.11% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-37.36%	-29.81%
Entrada Therapeutics	25.53%	16.11%	10.39%

Do analysts rate ZURA or TRDA?

Zura Bio currently has a consensus price target of $14.33, indicating a potential upside of 1,271.61%. Entrada Therapeutics has a consensus price target of $25.67, indicating a potential upside of 217.26%. Given Zura Bio's higher possible upside, equities research analysts plainly believe Zura Bio is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Entrada Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Do institutionals and insiders believe in ZURA or TRDA?

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 14.2% of Zura Bio shares are held by company insiders. Comparatively, 7.6% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer ZURA or TRDA?

Zura Bio received 2 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 84.62% of users gave Entrada Therapeutics an outperform vote while only 80.00% of users gave Zura Bio an outperform vote.

Company	Underperform	Outperform
Zura Bio	Outperform Votes 24 80.00%	Underperform Votes 6 20.00%
Entrada Therapeutics	Outperform Votes 22 84.62%	Underperform Votes 4 15.38%

Summary

Entrada Therapeutics beats Zura Bio on 11 of the 17 factors compared between the two stocks.